People with diabetes mellitus have substantially reduced numbers of pancreatic β-cells compared with healthy individuals. Now, a study in Science Translational Medicine demonstrates the efficacy of a dual tyrosine-regulated kinase 1A (DYRK1A) inhibitor treatment combined with a glucagon-like peptide 1 (GLP1) receptor agonist for increasing human β-cell mass in vivo.

The researchers transplanted human pancreatic islets under the kidney capsule of immunodeficient (Rag1^−/−) mice. These mice were treated for up to 3 months with either vehicle control, harmine, exendin 4 (a GLP1 receptor agonist) or a combination of harmine and exendin 4 (H&E). “We implemented a tissue clarification technique plus a light sheet microscopy approach called iDISCO+ to visualize in 3D the human islets transplanted under the kidney capsule,” says Garcia-Ocaña.

与健康人相比，糖尿病患者的胰腺β细胞数量大幅减少。现在， 《科学转化医学》上的一项研究证明了双重酪氨酸调节激酶​​ 1A (DYRK1A) 抑制剂联合胰高血糖素样肽 1 (GLP1) 受体激动剂治疗可有效增加人体内 β 细胞质量。

研究人员将人类胰岛移植到免疫缺陷 ( Rag1 ^−/− ) 小鼠的肾囊下。这些小鼠接受载体对照、去氢骆驼蓬碱、Exendin 4（一种 GLP1 受体激动剂）或去氢骆驼蓬碱和 Exendin 4 的组合 (H&E) 治疗长达 3 个月。 Garcia-Ocaña 说：“我们采用了一种组织澄清技术以及一种名为 iDISCO+ 的光片显微镜方法，以 3D 方式可视化移植到肾囊下的人类胰岛。”